To quell concerns over the politicization of a potential vaccine for the novel coronavirus, nine pharmaceutical companies developing a preventative treatment signed a pledge promising to uphold the integrity of the scientific process ahead of any potential approval of a medication.
At least four of six different vaccine candidates financially backed by the U.S. government aimed at the novel coronavirus are predicted to fail in the clinic, according to a draft report from an analytics group cited by CNBC.
AstraZeneca Plc has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of the company’s high-profile Covid-19 vaccine candidate.
The U.S. Food and Drug Administration’s approval-review schedule for August includes the Biologics License Application for Bristol Myers Squibb and Juno Therapeutics’ lisocabtagene maraleucel (liso-cel) for relapsed or refractory large B-cell lymphoma after at least two previous therapies.
The United States is tying payments for Covid-19 vaccines to timing milestones for production and approval, according to public documents and a Trump administration official, putting pressure on drugmakers including Moderna Inc. to meet ambitious targets.
(Reuters) – Any potential COVID-19 vaccine backed by the Trump administration’s “Operation Warp Speed” program is unlikely to receive a green light from regulators any earlier than November or December, […]
The United States entered an agreement with drugmaker Moderna Inc. to acquire 100 million doses of the company’s potential COVID-19 vaccine for around $1.5 billion, the company and White House said.
Omeros Corp.’s experimental treatment helped six patients with acute respiratory distress syndrome caused by Covid-19 recover and get discharged from the hospital, sending the drug developer’s shares up 60%.
GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a Covid-19 vaccine candidate under development by the two companies.
The National Institutes of Health is investing $248.7 million in seven diagnostic companies with new testing technologies to increase their testing capacities and make millions of rapid Covid-19 tests per week available by fall.
